AP NEWS

Malaria Pipeline Review - H1 2018: Key Players Involved in Therapeutic Development and Dormant & Discontinued Projects - ResearchAndMarkets.com

June 6, 2018

DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “Malaria - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews key players involved in therapeutic development for Malaria and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 11, 10, 56, 22 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 12, 47 and 34 molecules, respectively.

Key Topics Covered

Introduction Malaria - Overview Malaria - Therapeutics Development Malaria - Therapeutics Assessment Malaria - Companies Involved in Therapeutics Development Malaria - Drug Profiles Malaria - Dormant Projects Malaria - Discontinued Products Malaria - Product Development Milestones Appendix

Companies Mentioned

4SC AG AbbVie Inc Agilvax Inc Akshaya Bio Inc AlfaSigma SpA Allergy Therapeutics Plc Artificial Cell Technologies Inc AstraZeneca Plc Bharat Biotech Ltd Curevac AG Daiichi Sankyo Co Ltd DesignMedix Inc DMG Deutsche Malaria GmbH Eisai Co Ltd Fosun International Ltd Genzyme Corp GeoVax Labs Inc GlaxoSmithKline Plc iBio Inc Ichor Medical Systems Inc ID Pharma Co Ltd Immunovaccine Inc IPCA Laboratories Ltd Merck KGaA Microbiotix Inc Mitsubishi Tanabe Pharma Corp Novartis AG Osivax SAS Otsuka Holdings Co Ltd PaxVax Inc Pfizer Inc Protein Potential LLC Sanofi Takeda Pharmaceutical Co Ltd VLP Therapeutics LLC

For more information about this report visit https://www.researchandmarkets.com/research/zwlqkz/malaria_pipeline?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005592/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 06:41 AM/DISC: 06/06/2018 06:41 AM

http://www.businesswire.com/news/home/20180606005592/en

AP RADIO
Update hourly